Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects
Jan van Amsterdam, Tibor M. Brunt, Wim van den Brink
Journal of Psychopharmacology (2015) Vol. 29, Iss. 3, pp. 254-263
Closed Access | Times Cited: 231

Showing 1-25 of 231 citing articles:

Cannabis sativa: The Plant of the Thousand and One Molecules
Christelle M. André, Jean-François Hausman, Gea Guerriero
Frontiers in Plant Science (2016) Vol. 7
Open Access | Times Cited: 1288
An Introduction to the Endogenous Cannabinoid System
Hui‐Chen Lu, Ken Mackie
Biological Psychiatry (2015) Vol. 79, Iss. 7, pp. 516-525
Open Access | Times Cited: 1013
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Benedikt Fischer, Cayley Russell, Pamela Sabioni, et al.
American Journal of Public Health (2017) Vol. 107, Iss. 8, pp. e1-e12
Open Access | Times Cited: 364
Association Between Cannabis and Psychosis: Epidemiologic Evidence
Suzanne H. Gage, Matthew Hickman, Stanley Zammit
Biological Psychiatry (2015) Vol. 79, Iss. 7, pp. 549-556
Open Access | Times Cited: 337
Synthetic Cannabinoid–Related Illnesses and Deaths
Jordan Trecki, Roy Gerona, Michael D. Schwartz
New England Journal of Medicine (2015) Vol. 373, Iss. 2, pp. 103-107
Closed Access | Times Cited: 319
Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues
Samuel D. Banister, Mitchell Longworth, Richard C. Kevin, et al.
ACS Chemical Neuroscience (2016) Vol. 7, Iss. 9, pp. 1241-1254
Closed Access | Times Cited: 232
Positive and Negative Effects of Cannabis and Cannabinoids on Health
Koby Cohen, Abraham Weizman, Aviv Weinstein
Clinical Pharmacology & Therapeutics (2019) Vol. 105, Iss. 5, pp. 1139-1147
Closed Access | Times Cited: 215
Designer drugs: mechanism of action and adverse effects
Dino Luethi, Matthias E. Liechti
Archives of Toxicology (2020) Vol. 94, Iss. 4, pp. 1085-1133
Open Access | Times Cited: 212
Cannabis, cannabinoids, and health
Geneviève Lafaye, Laurent Karila, Lisa Blecha, et al.
Dialogues in Clinical Neuroscience (2017) Vol. 19, Iss. 3, pp. 309-316
Open Access | Times Cited: 210
Psychotic Disorders
Jeffrey A. Lieberman, Michael B. First
New England Journal of Medicine (2018) Vol. 379, Iss. 3, pp. 270-280
Closed Access | Times Cited: 195
Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants
Cristina Miliano, Giovanni Serpelloni, Claudia Rimondo, et al.
Frontiers in Neuroscience (2016) Vol. 10
Open Access | Times Cited: 183
Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health
Aviv Weinstein, Paola Rosca, Liana Fattore, et al.
Frontiers in Psychiatry (2017) Vol. 8
Open Access | Times Cited: 181
The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review
Vera L. Alves, João Gonçalves, Joselin Aguiar, et al.
Critical Reviews in Toxicology (2020) Vol. 50, Iss. 5, pp. 359-382
Closed Access | Times Cited: 153
Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective
Koby Cohen, Aviv Weinstein
Frontiers in Public Health (2018) Vol. 6
Open Access | Times Cited: 154
Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis
Liana Fattore
Biological Psychiatry (2016) Vol. 79, Iss. 7, pp. 539-548
Closed Access | Times Cited: 147
From niche to stigma—Headshops to prison: Exploring the rise and fall of synthetic cannabinoid use among young adults
Shane Blackman, Rick Bradley
International Journal of Drug Policy (2016) Vol. 40, pp. 70-77
Closed Access | Times Cited: 112
Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review
Ruwini Cooray, Veer Bala Gupta, Cenk Suphioglu
Molecular Neurobiology (2020) Vol. 57, Iss. 11, pp. 4878-4890
Open Access | Times Cited: 112
The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids—A Systematic Review
Koby Cohen, Aviv Weinstein
Brain Sciences (2018) Vol. 8, Iss. 3, pp. 40-40
Open Access | Times Cited: 109
Emerging drugs of abuse: current perspectives on synthetic cannabinoids
Danièle Debruyne, Reynald Le Boisselier
Substance Abuse and Rehabilitation (2015), pp. 113-113
Open Access | Times Cited: 106
Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis
Anahita Bassir Nia, Benjamin Medrano, Charles Perkel, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 12, pp. 1321-1330
Closed Access | Times Cited: 102
Closing the Yield Gap for Cannabis: A Meta-Analysis of Factors Determining Cannabis Yield
Rachel Backer, Timothy Schwinghamer, Phillip Rosenbaum, et al.
Frontiers in Plant Science (2019) Vol. 10
Open Access | Times Cited: 94
Acute Poisonings from Synthetic Cannabinoids — 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010–2015
Anne M. Riederer, Sharan Campleman, Robert G. Carlson, et al.
MMWR Morbidity and Mortality Weekly Report (2016) Vol. 65, Iss. 27, pp. 692-695
Open Access | Times Cited: 89
Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses
Zeinab Breijyeh, Buthaina Jubeh, Sabino Aurelio Bufo, et al.
Toxins (2021) Vol. 13, Iss. 2, pp. 117-117
Open Access | Times Cited: 84
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets
Rosa Maria Vitale, Fabio Arturo Iannotti, Pietro Amodeo
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4876-4876
Open Access | Times Cited: 63
The New Zealand drug harms ranking study: A multi-criteria decision analysis
Rose Crossin, Lana Cleland, Chris Wilkins, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 891-903
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top